吉利德科学公司的新药Livdelzi在治疗初级胆道胆炎方面显示出显著的益处, Gilead Sciences' new drug Livdelzi shows significant benefits in treating primary biliary cholangitis, with FDA approval.

Gilead Science的药物Livdelzi(seladelpar)在治疗初级口腔炎(PBC)方面显示出重大的好处,81%的病人获得了综合生化反应,41%的病人实现了关键肝功能标记的正常化。 Gilead Sciences' drug Livdelzi (seladelpar) showed significant benefits in treating primary biliary cholangitis (PBC), with 81% of patients achieving a composite biochemical response and 41% normalizing critical liver function markers. 三年来,该药物普遍使用良好,没有新的安全顾虑。 The drug was generally well-tolerated with no new safety concerns over three years. Livdelzi得到林业发展局对未对标准治疗作出适当反应的PBC患者的批准。 Livdelzi received FDA approval for PBC patients who have not responded adequately to standard treatment.

文章

Benzinga

WallStreet Online

HCPLive

-- 显示更少 --

延伸阅读

相关故事